Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Key facts

Sponsor

ECOG-ACRIN Cancer Research Group

Principal Investigator

Michael Lidsky

ECOG-ACRIN Cancer Research Group

Intervention

Bevacizumab(biological)

Enrollment

408 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2034

Study locations (30)

• University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
• UCHealth University of Colorado Hospital, Aurora, Colorado, United States
• UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Hollywood, Hollywood, Florida, United States
• University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
• Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
• University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
• Memorial Hospital East, Shiloh, Illinois, United States
• IU Health North Hospital, Carmel, Indiana, United States
• Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
• University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Fibrolamellar hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07521852
  A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
  TaiRx, Inc.
• RECRUITINGPHASE2NCT07504471
  Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
  Ruijin Hospital
• RECRUITINGNCT07295275
  Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
  West China Hospital
• RECRUITINGPHASE2NCT07324824
  Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
  Sun Yat-sen University
• RECRUITINGEARLY PHASE1NCT07193862
  Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
  Northwell Health
• RECRUITINGPHASE1, PHASE2NCT07282184
  Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
  Tongji Hospital
• RECRUITINGNCT07170345
  Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
  Chinese Academy of Sciences
• RECRUITINGPHASE2NCT07099274
  Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
  Tianjin Medical University Cancer Institute and Hospital

See all trials for Fibrolamellar hepatocellular carcinoma →